| Cinacalcet effect on severe hyperparathyroidism. | |
| | |
MedLine Citation:
|
PMID: 20814122 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
To determine the efficacy and safety of cinacalcet, a calcimimetic drug that suppress parathyroid hormone (PTH) production, we studied its effect on 20 patients (13 males) on maintenance hemodialysis (HD), 80% of them have persistent high PTH levels (i.e. more than 80 pmol/L), the remaining patients had PTH levels more than 60 pmol/L. Five of 20 (25%) patients dropped out from the study (2 because of severe GIT upset, one showed severe myalgia and arthralgia, one patient due to non compliance and one died at home due to cardiac arrest). The remaining 15 patients (10 males) had a mean age of 40 ± 12.86 years and dialysis duration of 29.13 ± 18.27 months. The follow-up period on cinacalcet was 4 months with a single daily oral dose started with 30 mg/day and increased gradually according to the PTH levels. Nine (60%) patients were on concomitant active vitamin D during the study period with a mean dose of 7.33 ± 3.39 μg/week. There was a significant decrease in the serum PTH levels at the end the study compared to that at the start (46.4 ± 4.7 pmol/L versus 93.3 ± 25.6 pmol/L, respectively, P< 0.000), and the target PTH level (< 31.6 pmol/L) was achieved in 54% of patients. No significant changes in serum Ca and phosphorous levels were observed. We conclude that cinacalcet is an effective therapy to suppress the serum PTH levels and allows favorable management of the serum calcium and phosphorus levels in HD patients. The drug was well tolerated; however, GIT discomfort is a significant side effect that may necessitate drug withdrawal in some patients. |
| | |
Authors:
|
Khalid Al Saran; Alaa Sabry; Ahmed Yehia; Azeb Molhem |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia Volume: 21 ISSN: 1319-2442 ISO Abbreviation: Saudi J Kidney Dis Transpl Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-09-03 Completed Date: 2010-11-23 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9436968 Medline TA: Saudi J Kidney Dis Transpl Country: Saudi Arabia |
Other Details:
|
Languages: eng Pagination: 867-71 Citation Subset: IM |
Affiliation:
|
Prince Salman Center for Kidney Disease, Riyadh, Saudi Arabia. Khalid_aln@yahoo.co.uk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Oral Adult Biological Markers / blood Calcium / blood Dietary Supplements Egypt Female Humans Hyperparathyroidism / drug therapy* Kidney Failure, Chronic / complications, therapy* Male Middle Aged Naphthalenes / administration & dosage, adverse effects, therapeutic use* Parathyroid Hormone / blood Phosphorus / blood Prospective Studies Renal Dialysis* Severity of Illness Index Time Factors Treatment Outcome Vitamin D / therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Naphthalenes; 0/PTH protein, human; 0/Parathyroid Hormone; 1406-16-2/Vitamin D; 364782-34-3/cinacalcet; 7440-70-2/Calcium; 7723-14-0/Phosphorus |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Hyperhomocysteinemia and cardiovascular risks in hemodialysis patients.
Next Document: Surrogate markers of subtle renal injury in patients with visceral leishmaniasis.